IMAGE

Fig. S9

ID
ZDB-IMAGE-180622-40
Source
Figures for Missinato et al., 2018
Image
Figure Caption

Fig. S9

BCI215 is specific for Dusp6 (A) Cryosections of WT and dusp6pt30a/+ hearts at 7 dpa injected for 6 days with DMSO (WT n=33; dusp6pt30a/+ n=17), or 0.25 mg/Kg of BCI215 (WT n=7; dusp6pt30a/+ n=11), stained for Mef2c and PCNA. (B) Quantification of cardiomyocyte proliferation in hearts injected with BCI215, or vehicle DMSO. Sub-optimal dose of BCI215 does not affect cardiomyocyte proliferation in WT hearts, but increases cardiomyocyte proliferation in dusp6pt30a/+ hearts. **p<0.01; n.s.=not significant. One-way ANOVA. (C) Cryosections of WT and dusp6pt30a/+ hearts at 7 dpa injected with DMSO (WT n=25; dusp6pt30a/+ n=15), or 0.5 mg/Kg of BCI215 (WT n=21; dusp6pt30a/+ n=8), stained for Mef2c and PCNA. (D) Quantification of cardiomyocyte proliferation. Optimal dose of BCI215 increases cardiomyocyte proliferation in WT hearts but it does not affect cardiomyocyte proliferation in dusp6pt30a/+ hearts ****p<0.0001; n.s.=not significant. One-way ANOVA. Scale bars, 100 μm.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Development